News

IN.PACT Drug-eluting Balloon Angioplasty IN.PACT SFA Clinical Trial

Patients with peripheral artery disease in the upper leg experienced significantly better outcomes at 12 months after treatment with the IN.PACT Admiral drug-coated balloon from Medtronic Inc....

Drug-eluting Balloon Angioplasty Clinical Study Trial Diabetes Restenosis

Despite good immediate results, in up to 40 percent of patients, obstructed arteries in the leg treated with a stent will again become blocked. This in-stent restenosis is typically treated with...

March 3, 2014 — Biotronik announced the release of its Passeo-18 Lux drug-releasing balloon (DRB) in all countries...

Bard Drug Coated Balloon Below the Knee Clinical Trial Peripheral Artery Disease

Experts presented six-month LEVANT 2 trial results for C. R. Bard Inc.’s Lutonix drug coated balloon (DCB) and provided updates on the ongoing Lutonix Below the Knee (BTK) Clinical Trial...

ACC, iPad cardiology apps

DAIC readers chose the following stories as the most popular content in 2013, based on website analytics.

balloon catheters cath lab drug-eluting clinical trials angioscore angiosculpt

AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease...

bard, DEB, drug eluting balloon

The first clinical trial in the United States to study the use of drug-coated ...

The global sales of drug-eluting balloons (DEBs) across the 10 major markets (10MM) are expected to witness a significant increase over the coming years, from $164m in 2012 to $477m in...

August 19, 2013 — Medtronic Inc. announced the submission of its first pre-market approval (PMA) module to the U.S. Food and Drug Administration (FDA) for the IN.PACT Admiral drug-eluting balloon...

One-year data from an Italian multicenter randomized controlled trial of the In.Pact Falcon drug-eluting balloon from Medtronic Inc. demonstrate positive and durable clinical results with the...

Biosensors International Group Ltd. has entered into a licensing agreement with Eurocor GmbH, a group company of Opto Circuits (India) Ltd. for their drug eluting balloon (DEB) technology and...

Lutonix Drug Coated Balloon C. R. Bard Inc. PAD Treatments Clinical Trial

C. R. Bard Inc. announced the enrollment of the first patient into the Lutonix Below the Knee (BTK) Clinical Trial at The Cardiac and Vascular Institute in Gainesville, Fla. The purpose of this...

Vascular Nanotransfer Technologies (VNT) says it has developed the industry’s most versatile drug-coated-balloon (DCB) platform designed to deliver a wide variety of drugs for best-in-class DCB...

Top stories of 2012 in cardiology

To help identify trends and find out what DAIC readers are interested in, the magazine takes note of what they click on when visiting the website. Below are the top 25 stories from 2012, and the...

December 26, 2012 — Covidien announced a definitive agreement to acquire CV Ingenuity. The companies expect to complete the acquisition in the first calendar quarter of 2013. Financial...

Primus Drug-Eluting Balloon Balloon Catheters Peripheral Artery Disease devices

November 1, 2012 — It looks as though drug-eluting balloons (DEBs), already widely used in Europe, are set to burst...

Primus Drug-Eluting Balloon

September 21, 2012 — Cardionovum GmbH announced that the results of a preclinical study and a first-in-man clinical study of its Primus drug-coated balloon (DCB) will be published in the October...

July 27, 2012 — C. R. Bard Inc. announced that its Lutonix technology center has completed patient enrollment into its global, multicenter LEVANT 2 randomized clinical trial.

July 9, 2012 — Cardionovum GmbH announced it has initiated in vivo testing of its second drug-eluting balloon (DEB) Restore. The company is currently marketing a line...

June 13, 2012 — Physicians presented at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing statistically significant...

April 17, 2012 –– Expanding its commitment to developing innovative treatments for cardiovascular disease and the evidence to support their adoption, Medtronic announced the start of the Medtronic...

March 20, 2012 - MarBlue Medical announced the global product launch of its CE-marked drug-eluting balloon (DEB) Protege as well as its CoCr stent on DEB Pioneer. The full market launch of the new...

January 25, 2012 — Physicians at University Hospitals (UH) Case Medical Center enrolled their first patient in LEVANT 2, a global, multicenter, randomized clinical trial evaluating the safety and...

January 6, 2012 - C. R. Bard recently announced it acquired drug-eluting balloon maker Lutonix Inc. for $225 million. Following successful approval of a U.S. Food and Drug Administration (FDA) pre...

December 28, 2011 – Good Samaritan Hospital in Los Angeles is participating in the Levant 2 clinical trial to investigate a potential new treatment option for people with peripheral artery disease...

November 14, 2011 – Medrad Inc. announced that five-year data from the THUNDER trial [1] demonstrated a 59 percent relative reduction in target lesion revascularization (TLR) rates in popliteal...

November 14, 2011 — A clinical trial of patients with restenosis in drug-eluting stents (DES) in native coronary arteries found treatment with paclitaxel-coated balloon angioplasty demonstrated...

September 15, 2011 – The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular...

September 15, 2011 — Very positive results were reported in the first account of a clinical study evaluating the effectiveness of angioplasty with drug-eluting balloons for critical limb ischemia...

July 26, 2011 – The first patient has been enrolled in the LEVANT 2 clinical trial, a global, multi-center, randomized trial evaluating the safety and efficacy of Lutonix’s Moxy drug-coated...

May 17, 2011 - Medrad Inc., a business of Bayer HealthCare, today announced it has received CE Mark for its Cotavance Paclitaxel Coated Balloon Angioplasty Catheter with Paccocathtechnology. The...

November 17, 2010 – A drug-eluting balloon (DEB) and a coronary stent have received CE mark approval in Europe. The DEB and the coronary CoCr stent, both by Blue Medical, have been approved for...

September 29, 2010 – Results from a trial studying the effects of a drug-eluting balloon (DEB) on peripheral artery disease (PAD) were released at the Transcatheter Cardiovascular Therapeutics (...

May 25, 2010 – The first patient has been implanted with a bare metal coronary stent mounted on a drug-eluting balloon in the European Pioneer trial, which began this week.

February 22, 2010 – As part of a comarketing and trademark license agreement between MEDRAD Inc. and B. Braun Melsungen AG, the companies will both promote the Paccocath drug-eluting balloon (DEB...

January 25, 2010 – Expanding its peripheral vascular disease product offerings, Medtronic Inc. today signed an agreement to acquire Invatec and two affiliated companies.

May 19, 2009 - Invatec announced today the availability of its newly CE-marked coronary balloon, the IN.PACT Falcon paclitaxel-eluting PTCA balloon catheter at the EuroPCR Congress 2009 in...

March 16, 2009 – Invatec today announced CE-certification of a new coronary balloon, the IN.PACT Falcon paclitaxel-eluting PTCA balloon catheter, which is one of the first drug-eluting balloons...

January 13, 2009 - Micell Technologies, a development-stage biomedical device company dedicated to developing innovative interventional cardiology systems, has obtained the rights to Maxcor's CE-...

October 24, 2007 — Drug-eluting balloons could offer a viable alternative to drug-eluting stents (DES) in the treatment of coronary artery disease, according to research results from two studies...